This study is not yet accepting patients
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles 5368361, California 5332921 and other locations
- Dates
- study startedstudy ends around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Newron Pharmaceuticals SPA
- ID
- NCT07184619
- Phase
- Phase 3 Schizophrenia Research Study
- Study Type
- Interventional
- Participants
- Expecting 400 study participants
- Last Updated